IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.260
EU - Europa 2.231
AS - Asia 876
OC - Oceania 6
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.258
IE - Irlanda 667
SE - Svezia 527
CN - Cina 391
SG - Singapore 377
IT - Italia 322
PL - Polonia 188
GB - Regno Unito 185
FI - Finlandia 99
UA - Ucraina 75
DE - Germania 65
IN - India 38
VN - Vietnam 33
AT - Austria 24
ID - Indonesia 22
BE - Belgio 19
FR - Francia 13
NL - Olanda 9
CZ - Repubblica Ceca 8
ES - Italia 7
RU - Federazione Russa 7
AU - Australia 5
HK - Hong Kong 4
KR - Corea 4
GR - Grecia 3
IQ - Iraq 3
CH - Svizzera 2
CL - Cile 2
EC - Ecuador 2
EU - Europa 2
NO - Norvegia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
CA - Canada 1
EE - Estonia 1
HR - Croazia 1
IL - Israele 1
LT - Lituania 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 5.382
Salva come PNG Salva come JPEG
Città #
Dublin 667
Chandler 422
Singapore 307
Nyköping 306
Jacksonville 228
Warsaw 188
Beijing 161
Messina 148
Lancaster 144
Princeton 132
Medford 121
Ashburn 111
Dearborn 98
Cambridge 90
Des Moines 89
Ann Arbor 77
New York 56
Wilmington 37
Boardman 36
Los Angeles 35
Dong Ket 32
Shenyang 27
Jinan 26
San Mateo 26
Jakarta 22
Pune 22
Vienna 22
Brussels 19
Seattle 19
Rome 16
Nanjing 14
Houston 13
Tianjin 13
Woodbridge 12
Zhengzhou 12
Hebei 11
Ningbo 10
Catania 9
Helsinki 9
Paternò 9
Redwood City 9
Hyderabad 8
Lappeenranta 8
Milan 8
Scarsdale 8
Taizhou 8
Brno 7
Fuzhou 7
Changsha 6
Washington 6
Jiaxing 5
Nanchang 5
Vitoria 5
Bremen 4
Haikou 4
Lanzhou 4
Munich 4
Nuremberg 4
Amsterdam 3
Clearwater 3
Falls Church 3
Guangzhou 3
Hangzhou 3
Hanover 3
Hefei 3
Hong Kong 3
London 3
Najaf 3
New Delhi 3
Novokuznetsk 3
Shanghai 3
Sydney 3
Aci Castello 2
Bordeaux 2
Calvisano 2
Chicago 2
Edinburgh 2
Frankfurt am Main 2
Fremont 2
Gravina di Catania 2
Indore 2
Lima 2
Linguaglossa 2
Modena 2
Mumbai 2
Norwalk 2
Piazza Armerina 2
Polomka 2
Qingdao 2
Quito 2
Ravenna 2
Riva 2
Romano di Lombardia 2
Saint Petersburg 2
Sheffield 2
Tangshan 2
The Dalles 2
Yangcheon-gu 2
Apo 1
Athens 1
Totale 4.002
Salva come PNG Salva come JPEG
Nome #
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 113
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 100
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 89
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 87
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 83
Liquid biopsy for lung cancer early detection 79
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 78
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 74
Targeted drugs in small-cell lung cancer 71
Applications of genomics in NSCLC 70
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 70
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 69
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 68
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 67
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 67
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 67
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 65
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 65
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 65
On the pharmacogenetics of non-small cell lung cancer treatment 65
Activation of viral defense signaling in cancer 65
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 63
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 62
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 61
PIK3CA mutations in breast cancer: a potential marker 59
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 59
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 57
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 55
Usefulness of predictive tests for cancer treatment 55
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 54
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 53
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 52
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 52
Beyond platinum treatment for NSCLC: what does the future hold? 51
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 51
Advances in immunotherapy for treatment of lung cancer 50
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 50
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 50
Mucocutaneous toxicity induced by pegylated liposomal doxorubicin. A single institution, retrospective case series 50
Emerging drugs for non-small-cell lung cancer. 49
TRANSLATIONAL RESEARCH IN GLIOBLASTOMA MULTIFORME: A REVIEW OF MOLECULAR CRITERIA FOR PATIENT SELECTION 48
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 47
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 46
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 46
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 46
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 46
Implications of XPD312 in stage IIIA-B NSCLC 44
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are andwhere we are going 44
PIK3CA mutations in breast cancer: A potential predictive marker 43
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 43
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 43
Feasibility of cell-free circulating tumor DNA testing for lung cancer 43
null 43
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 42
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 41
Tossicità ungueale in corso di trattamento con doxorubicina liposomiale: studio retrospettivo di un singolo centro 41
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 41
Immunotherapy in NSCLC: A promising and revolutionary weapon 41
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 41
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 41
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 40
null 40
Novel mutations in the NFkB and NOTCH pathways 39
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 39
P1.03-14 HLA-E and FAT1 in Head and Neck and Lung Cancer. The Effect of Osimertinib or Olmutinib with Artesunate (Dihydroartemisinin) 38
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 38
Mosaicism in von Hippel-Lindau disease: an event important to recognize 37
Methylation of Mad2 in serum DNA of docetaxel/cisplatin-treated stage IV non-small-cell lung cancer. 37
Immunotherapeutic Advances for NSCLC 36
Human endogenous retroviruses and cancer 36
Nail toxicities induced by liposomal doxorubicin: A retrospective case series 36
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 36
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 36
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 36
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 35
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape 35
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 35
Subcutaneous low-dose alemtuzumab as first line therapy for elderly CLL patients with deletion of 17p 34
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 34
Predicting the outcome of chemotherapy for lung cancer. 33
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response 33
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer 33
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung 32
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 32
Terra firma-forme dermatosis 31
BRCA1 and anti-angiogenesis: new perspectives on the treatment of non-small-cell lung cancer 31
null 31
Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP) 30
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 30
Melanoma: oncogenic drivers and the immune system 29
Tumor immune microenvironment characterization and response to anti-PD-1 therapy 29
Recent developments in the use of immunotherapy in non-small cell lung cancer 29
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 28
Triple-negative breast cancer 28
Targeting PD-I/PD-LI in lung cancer: Current perspectives 28
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery 28
Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: A retrospective study 28
Increased detection of circulating tumor DNA by short fragment enrichment 28
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 27
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. 27
Totale 4.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.106
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020351 0 0 0 0 0 0 55 42 8 116 107 23
2020/2021788 48 16 127 44 155 59 40 82 67 88 19 43
2021/2022796 6 37 32 31 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/2025560 47 31 66 145 155 110 6 0 0 0 0 0
Totale 5.750